Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China

2023年 9月 18日

Read More

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China

2023年 8月 30日

Read More

Zai Lab Announces Participation in September Investor Conferences

2023年 8月 29日

Read More

Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates

2023年 8月 07日

Read More

Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023

2023年 7月 20日

Read More

JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

2023年 7月 19日

Read More

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

2023年 7月 17日

Read More

Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

2023年 7月 14日

Read More